ACHIEVE LIFE SCIENCES INC (ACHV) Stock News

Achieve Life Sciences to Present at the Oppenheimer Healthcare Life Sciences Conference

SEATTLE and VANCOUVER, British Columbia, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty...

Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial

No Safety Concerns Identified by DSMC in the ORCA-OL Long-Term Exposure Trial Achieve Reiterates Planned Cytisinicline NDA Submission in Q2 2025 SEATTLE...

Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors

New Directors Bring Extensive Leadership Experience in Corporate Strategy and Commercialization...

Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission

Over 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure Requirement...

Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

SEATTLE and VANCOUVER, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical...

ACHV Stock Earnings: Achieve Life Sciences Misses EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Achieve Life Sciences (NASDAQ:ACHV) just reported results for the second quarte...

ACHV Stock Earnings: Achieve Life Sciences Misses EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Achieve Life Sciences (NASDAQ:ACHV) just reported results for the first quarter...

ACHV Stock Earnings: Achieve Life Sciences Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Achieve Life Sciences (NASDAQ:ACHV) just reported results for the fourth quarte...

Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer

SEATTLE and VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical...

Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA

Milestone Reinforces the Potential for Cytisinicline as a First-in-Class Treatment for Vaping Cessation...

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

SEATTLE and VANCOUVER, British Columbia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical...

This Turning Point Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Mentions: RMTI CSL TPB ADIL

Achieve Life Sciences President and CMO, Dr. Cindy Jacobs, Speaks at FDA and NIH Smoking Cessation Public Meeting

SEATTLE and VANCOUVER, British Columbia, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical...

Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline

SEATTLE and VANCOUVER, British Columbia, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical...

Recap: Achieve Life Sciences Q4 Earnings

Achieve Life Sciences Strengthens Leadership with Appointment of Dr. Mark Rubinstein, Nicotine Dependence Expert, as New Head of Medical Affairs

SEATTLE and VANCOUVER, British Columbia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical...

Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors

Richard Stewart reassumes role of Chief Executive Officer Thomas King appointed Executive Chairman of the Board of Directors SEATTLE and VANCOUVER,...

ACHV Stock Earnings: Achieve Life Sciences Misses EPS for Q2 2024

ACHV stock results show that Achieve Life Sciences missed analyst estimates for earnings per share the second quarter of 2024.

Achieve Life Sciences Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

Company to host conference call at 4:30 PM EDT today, Tuesday, August 13, 2024...

Achieve Life Sciences Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine Dependence

Designation is based on results from the Phase 2 ORCA-V1 trial that showed treatment with cytisinicline more than doubled the odds of quitting e-cigarettes...

Achieve Life Sciences Announces $20M Loan Refinancing with Silicon Valley Bank

SEATTLE and VANCOUVER, British Columbia, July 29, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical...

Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 13, 2024

SEATTLE and VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical...

Achieve Life Sciences to Present at JonesHealthcare Seaside Summit 2024

SEATTLE and VANCOUVER, British Columbia, July 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical...

Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting

SEATTLE and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company...

ACHV Stock Earnings: Achieve Life Sciences Misses EPS for Q1 2024

ACHV stock results show that Achieve Life Sciences missed analyst estimates for earnings per share the first quarter of 2024.

Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update

Company to host conference call at 4:30 PM EDT today, Thursday, May 9, 2024...

Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine

Phase 2 ORCA-V1 trial showed treatment with cytisinicline more than doubled odds of quitting e-cigarettes compared with placebo   Cytisinicline treatment...

Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 9, 2024

SEATTLE and VANCOUVER, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical...

ACHV Stock Earnings: Achieve Life Sciences Beats EPS for Q4 2023

ACHV stock results show that Achieve Life Sciences beat analyst estimates for earnings per share the fourth quarter of 2023.

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update

Company to host conference call at 4:30 PM EDT today, Thursday, March 28, 2024...

Life Science Virtual Investor Forum Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Mentions: LSTA KRBP SYRA MRDH

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

SEATTLE and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical...

Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Mentions: LSTA KRBP SYRA

Achieve Life Sciences stock falls 11% amid FDA update, securities sale (NASDAQ:ACHV)

Achieve Life Sciences (ACHV) stock fell 11% amid news it plans to conduct an additional clinical study for its drug cytisinicline and a securities offering worth up to $124.2M.

Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission

Open-label exposure trial expected to initiate in Q2’24 with NDA filing anticipated in 1H 2025...

Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement

$60 million financing upfront with up to an additional $64.2 million tied to exercise of milestone-driven warrants Upfront net proceeds to provide funds...

Life Science Investor Forum: Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Mentions: BABY.CA NRBO RVPH KA